|Dr. J. Joseph Kim||CEO, Pres & Director||1.14M||609.55k||1969|
|Mr. Peter D. Kies||Chief Financial Officer||618.22k||35.76k||1963|
|Dr. Jacqueline E. Shea||COO & Exec. VP||N/A||N/A||1966|
|Dr. Mark L. Bagarazzi||Chief Medical Officer||N/A||N/A||1961|
|Dr. Laurent M. Humeau||Chief Scientific Officer & Exec. VP||N/A||N/A||1967|
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 4. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 3; Compensation: 8.